title: High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.
abstract: BACKGROUND
  Carbonic anhydrase IX (CAIX) is an enzyme upregulated by hypoxia during tumour development and progression. This study was conducted to assess if the expression of CAIX in tumour tissue and/or plasma can be a prognostic factor in patients with non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Tissue microarrays containing 555 NSCLC tissue samples were generated for quantification of CAIX expression. The plasma level of CAIX was determined by ELISA in 209 of these NSCLC patients and in 58 healthy individuals. The CAIX tissue immunostaining and plasma levels were correlated with clinicopathological factors and patient outcome.
  
  
  RESULTS
  CAIX tissue overexpression correlated with shorter overall survival (OS) (P=0.05) and disease-specific survival (DSS) of patients (P=0.002). The CAIX plasma level was significantly higher in patients with NSCLC than in healthy individuals (P<0.001). A high level of CAIX in the plasma of patients was associated with shorter OS (P<0.001) and DSS (P<0.001), mostly in early stage I+II NSCLC. Multivariate Cox analyses revealed that high CAIX tissue expression (P=0.002) was a factor of poor prognosis in patients with resectable NSCLC. In addition, a high CAIX plasma level was an independent variable predicting poor OS (P<0.001) in patients with NSCLC.
  
  
  CONCLUSIONS
  High expression of CAIX in tumour tissue is a predictor of worse survival, and a high CAIX plasma level is an independent prognostic biomarker in patients with NSCLC, in particular in early-stage I+II carcinomas.
authors.affiliation: Laboratory of Clinical and Experimental Pathology, Louis Pasteur Hospital, Nice, France.
authors.forename: M
authors.initials: M
authors.lastname: Ilie
authors.forename: N M
authors.initials: NM
authors.lastname: Mazure
authors.forename: V
authors.initials: V
authors.lastname: Hofman
authors.forename: R E
authors.initials: RE
authors.lastname: Ammadi
authors.forename: C
authors.initials: C
authors.lastname: Ortholan
authors.forename: C
authors.initials: C
authors.lastname: Bonnetaud
authors.forename: K
authors.initials: K
authors.lastname: Havet
authors.forename: N
authors.initials: N
authors.lastname: Venissac
authors.forename: B
authors.initials: B
authors.lastname: Mograbi
authors.forename: J
authors.initials: J
authors.lastname: Mouroux
authors.forename: J
authors.initials: J
authors.lastname: Pouysségur
authors.forename: P
authors.initials: P
authors.lastname: Hofman
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood* / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000097:blood* / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000175:diagnosis* / Q000378:metabolism / Q000401:mortality; D015687:Cell Hypoxia / Q000502:physiology; D049109:Cell Proliferation; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000378:metabolism / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D046888:Tissue Array Analysis; D015854:Up-Regulation
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases
references.citation: Br J Cancer. 2008 Mar 11;98(5):956-64
references.pmid: 18268492
references.citation: Anticancer Res. 2000 May-Jun;20(3A):1527-33
references.pmid: 10928066
references.citation: Cancer Res. 2001 Jul 1;61(13):5262-7
references.pmid: 11431368
references.citation: Lung Cancer. 2009 Sep;65(3):355-62
references.pmid: 19162366
references.citation: Br J Cancer. 2005 Jan 17;92(1):94-101
references.pmid: 15558070
references.citation: Cell Death Differ. 2001 Apr;8(4):367-76
references.pmid: 11550088
references.citation: Neoplasma. 2009;56(4):298-302
references.pmid: 19473055
references.citation: Lung Cancer. 2006 Apr;52(1):59-66
references.pmid: 16513206
references.citation: Lung Cancer. 2006 Dec;54(3):409-18
references.pmid: 17030461
references.citation: Cancer. 2000 Mar 1;88(5):1108-21
references.pmid: 10699902
references.citation: Proc Am Thorac Soc. 2009 Apr 15;6(2):233-41
references.pmid: 19349493
references.citation: Br J Cancer. 2005 Nov 28;93(11):1267-76
references.pmid: 16278664
references.citation: Clin Cancer Res. 2003 Nov 15;9(15):5666-74
references.pmid: 14654550
references.citation: Nat Rev Cancer. 2003 Oct;3(10):721-32
references.pmid: 13130303
references.citation: Curr Opin Biotechnol. 2008 Feb;19(1):19-25
references.pmid: 18053705
references.citation: J Korean Med Sci. 2003 Apr;18(2):196-203
references.pmid: 12692416
references.citation: Lung Cancer. 2009 Jun;64(3):271-6
references.pmid: 19022520
references.citation: Cancer Res. 1999 Nov 15;59(22):5830-5
references.pmid: 10582706
references.citation: J Mol Med (Berl). 2007 Dec;85(12):1301-7
references.pmid: 18026916
references.citation: J Clin Oncol. 2003 Feb 1;21(3):473-82
references.pmid: 12560438
references.citation: Eur J Cancer. 2005 Dec;41(18):2935-47
references.pmid: 16310354
references.citation: Hum Pathol. 2008 Sep;39(9):1317-22
references.pmid: 18440050
references.citation: Clin Cancer Res. 2003 Feb;9(2):802-11
references.pmid: 12576453
references.citation: Control Clin Trials. 1996 Aug;17(4):343-6
references.pmid: 8889347
references.citation: J Urol. 2008 Aug;180(2):510-3; discussion 513-4
references.pmid: 18550116
references.citation: Br J Cancer. 2003 Sep 15;89(6):1067-71
references.pmid: 12966427
references.citation: Clin Cancer Res. 2004 Dec 1;10(23):7925-33
references.pmid: 15585626
references.citation: Int J Oncol. 2004 Apr;24(4):995-1004
references.pmid: 15010840
references.citation: Nat Cell Biol. 2000 Jul;2(7):423-7
references.pmid: 10878807
references.citation: Br J Cancer. 2009 Mar 24;100(6):874-80
references.pmid: 19240720
references.citation: Cancer. 2009 Apr 1;115(7):1448-58
references.pmid: 19195047
references.citation: J Biol Chem. 2008 Oct 10;283(41):27799-27809
references.pmid: 18703501
references.citation: Cancer. 2007 Oct 1;110(7):1532-41
references.pmid: 17702091
references.citation: Cancer Res. 2009 Jan 1;69(1):358-68
references.pmid: 19118021
references.citation: Int J Cancer. 2007 Apr 1;120(7):1451-8
references.pmid: 17245699
references.citation: Nat Rev Drug Discov. 2008 Feb;7(2):168-81
references.pmid: 18167490
references.citation: Chest. 1997 Jun;111(6):1710-7
references.pmid: 9187198
references.citation: Br J Cancer. 2008 Jan 15;98(1):129-36
references.pmid: 18026188
references.citation: Cancer Res. 2002 Apr 1;62(7):1931-4
references.pmid: 11929804
references.citation: J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229
references.pmid: 15499993
references.citation: Br J Cancer. 2002 Apr 22;86(8):1276-82
references.pmid: 11953885
references.citation: Oncogene. 1994 Jun;9(6):1599-604
references.pmid: 8183553
references.citation: Curr Oncol Rep. 2005 Mar;7(2):109-15
references.pmid: 15717944
references.citation: Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):161-9
references.pmid: 18722267
references.citation: Clin Cancer Res. 2001 Nov;7(11):3399-403
references.pmid: 11705854
references.citation: Lung Cancer. 2005 Sep;49(3):325-35
references.pmid: 15935515
references.citation: Cancer Res. 2000 Dec 15;60(24):7075-83
references.pmid: 11156414
references.citation: Int J Cancer. 2004 Aug 10;111(1):43-50
references.pmid: 15185341
references.citation: Cancer Res. 2001 Sep 1;61(17):6394-9
references.pmid: 11522632
references.citation: Nature. 2006 May 25;441(7092):437-43
references.pmid: 16724055